Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of FcεRI in mast cells
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxac097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Caijie Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Longgang Traditional Chinese Medicine Hospital and Beijing University of Chinese Medicine Shenzhen Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Receptors, IgE, Rhinitis, Allergic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Nature and Science Foundation of China, Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Joint Youth Fund for Basic and Applied Basic Research of Guangdong Province.
Abstract (Originalsprache)
The high-affinity IgE receptor, FcεRI, plays a key role in the antigen-induced mast cell activation. Regulations for FcεRI are not yet well understood. TAFA4 is a molecule derived from neuron tissues, and has immune regulation functions. This study aims to clarify the role of TAFA4 in the regulation of FcεRI expression in mast cells. Nasal secretions were collected from patients with allergic rhinitis (AR) and healthy control (HC) subjects. TAFA4 levels of nasal secretions were evaluated by ELISA. A mouse model AR was developed using ovalbumin as the specific antigen. Negative correlation between TAFA4 and tryptase levels in nasal secretions was observed. TAFA4 could suppress the antigen-related mast cell activation. TAFA4 modulated the transcription of Fcer1g (FcεRI γ gene) in mast cells. Signals from the TAFA4-PTEN-PU.1 axis restricted FcεRI expression in mast cells. Administration of TAFA4 attenuated experimental AR. TAFA4 suppressed the expression of FcεRI in mast cells of airway tissues. TAFA4 can down regulate the expression of FcεRI in mast cells to suppress experimental AR. The data suggest that TAFA4 has translation potential to be developed as an anti-allergy therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Longgang Traditional Chinese Medicine Hospital and Beijing University of Chinese Medicine Shenzhen Hospital, Shenzhen, China.
- Department of Respirology & Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
- Guangdong Provincial Regional Disease Key Laboratory, Shenzhen, China.
- Institute of Allergy & Immunology of Shenzhen University, State Key Laboratory of Respiratory Diseases Allergy Division at Shenzhen University, Shenzhen, China.
ORCID-Profile: Pingchang Yang
Förderung
- National Nature and Science Foundation of China
- Guangdong Provincial Key Laboratory of Regional Immunity and Diseases
- Joint Youth Fund for Basic and Applied Basic Research of Guangdong Province
- International Cooperative Research Project of Shenzhen Collaborative Innovation Program
- Shenzhen science, technology and innovation committee
Zitieren
APA
Zhou, C., Li, M., Liu, Y., Wang, X., Zhang, S., Guan, L., Hong, J., Zhou, W., Wu, G., Diao, W., Huang, Q., & Yang, P. (2023). Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of FcεRI in mast cells. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxac097
Vancouver
Zhou C, Li M, Liu Y, Wang X, Zhang S, Guan L, et al. Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of FcεRI in mast cells. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxac097
BibTeX
@article{Zhou2023,
author = {Zhou, Caijie and Li, Meihua and Liu, Yu and Wang, Xinxin and Zhang, Shuang and Guan, Li and Hong, Jingyi and Zhou, Wei and Wu, Gaohui and Diao, Weiliang and Huang, Qinmiao and Yang, Pingchang},
title = {Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of FcεRI in mast cells},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxac097}
}
EUVIMED